Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

We don’t have any long-term studies at this point, but all of the ones that have come out point not only to the use of the ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...

There are five projects from Tullamore College. 'Perimenopause Uncovered: Empowering women through knowledge' was entered by ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Drug ads on TV are so ubiquitous that they make one long for detergent or cereal ads to break the monotony. If the incoming ...

From GLP-1s to brand product innovation, the trend intelligence report details the overall surge of innovation and investment in women’s health technologies at the 2025 CES on Monday.

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

Vermont is the most expensive state for health care, while Hawaii is the most affordable. Six of the 10 most expensive states for health care are in the South: Tennessee, Texas, North Carolina, ...

With multiple stakeholders involved with different interests, the “specialty drug” definition can be a moving target.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Naltrexone is cheap and has the potential to stop dangerous drinking, so why is it not used everywhere? Sophie Gallagher ...